Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- Available as individual single pills, in fixed-dose combination cobicistat/darunavir, or in fixed-dose single-tablet regimen cobicistat/darunavir/emtricitabine/tenofovir AF[FDA Cobicistat; FDA Cobicistat/darunavir; FDA DRV COBI FTC TAF]
- Cobicistat/darunavir/emtricitabine/tenofovir AF approval by the FDA in July 2018 provides first-ever PI-based single-tablet ART regimen
- Approval of cobicistat/darunavir based only on pharmacokinetic equivalency to darunavir plus ritonavir combination
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Initial Antiretroviral Therapy